Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
A randomized trial conducted by the Gynecologic Oncology Group in women with suboptimal residual advanced ovarian cancer has shown that the combination chemotherapy regimen of cisplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) results in a higher objective response rate, as well as improved progression-free and overall survival, compared with treatment with cisplatin and cyclophosphamide. Future clinical research efforts in this area will likely focus on attempting to optimize the delivery of a platinum agent and paclitaxel, as well as on adding agents with demonstrated activity in this malignancy to the regimen.
Markman
M
M
The Cleveland Clinic Cancer Center and the Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects
D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin